Companies · Pharmaceuticals
SANTA CLARA · Pharmaceuticals
Diligence memoA one-page analyst read on Xenoport Inc — recommendation, valuation, rhythm, risks.→Xenoport Inc looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Xenoport Inc is one of 1613 Pharmaceuticals companies tracked from SANTA CLARA. By capital raised it ranks mid-pack (ahead of 66% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 66% of sector peers (real $). Modeled value above 85% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #25 of 47.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Celator Pharmaceuticals Inc | Series B | $63.5M | $1.3B | 1.80× |
| Kythera Biopharmaceuticals Inc | Series B | $37.4M | $1.3B | 1.72× |
| Palatin Technologies Inc | Series B | $35.0M | $1.2B | 1.61× |
| Pernix Therapeutics Holdings, Inc. | Series B | $34.0M | $1.2B | 1.56× |
| CEBIX Inc | Series B | $76.3M | $1.1B | 1.53× |
| Topica Pharmaceuticals Inc | Series B | $51.5M | $1.1B | 1.45× |
| Supernus Pharmaceuticals Inc | Series B | $45.0M | $1.0B | 1.38× |
| Cornerstone Therapeutics Inc | Series B | $30.0M | $1.0B | 1.38× |
| Derma Sciences, Inc. | Series B | $29.1M | $988.7M | 1.34× |
| iPierian, Inc. | Series B | $87.3M | $985.1M | 1.33× |
| Sunesis Pharmaceuticals Inc | Series B | $38.5M | $969.1M | 1.31× |
| Cardioxyl Pharmaceuticals Inc | Series B | $52.0M | $953.8M | 1.29× |
| Xenoport Inc this company | Series B | $20.0M | $680.1M | 0.92× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series B | $20.0M | 2012-11-08 | $111.1M | $680.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| John G. Freund | — | 5 other | 2012-11 |
| William J. Rieflin | — | 3 other | 2012-11 |
| David R. Savello | — | 1 other | 2012-11 |
| Jeryl L. Hilleman | — | 1 other | 2012-11 |
| Paul L. Berns | — | 1 other | 2012-11 |
| Vincent J. Angotti | — | 1 other | 2012-11 |
| Wendell J. Wierenga | — | 1 other | 2012-11 |
| William G. Harris | — | 1 other | 2012-11 |
| Catherine J. Friedman | — | — | 2012-11 |
| Dennis M. Fenton | — | — | 2012-11 |
| Ernest L. Mario | — | — | 2012-11 |
| Gianna M. Bosko | — | — | 2012-11 |
| Gregory T. Bates | — | — | 2012-11 |
| Ronald W. Barrett | — | — | 2012-11 |
Xenoport Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Ocera Therapeutics, Inc. | Pharmaceuticals | Series B | $50.0M | $952.1M | network1 shared operator · same sector · same stage |
| Talphera, Inc. | Pharmaceuticals | Series B | $97.4M | $74.2M | network1 shared operator · same sector · same stage |
| CutisPharma, Inc. | Pharmaceuticals | Series B | $20.0M | $680.1M | same sector · same stage |
| Fibrogen Inc | Pharmaceuticals | Series B | $20.0M | $680.1M | same sector · same stage |
| Stemtrix Corp. | Pharmaceuticals | Series B | $20.0M | $242.3M | same sector · same stage |
| Tyme Technologies, Inc. | Pharmaceuticals | Series B | $20.0M | $680.1M | same sector · same stage |
| Alnara Pharmaceuticals Inc | Pharmaceuticals | Series B | $20.0M | $679.9M | same sector · same stage |
| Trillium Therapeutics Inc. | Pharmaceuticals | Series B | $20.0M | $679.2M | same sector · same stage |
See where Xenoport Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Xenoport Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.